About The Cover
The cover for issue 51 of Oncotarget features Figure 5, "miR-4287 overexpression regulates EMT in prostate cancer cell lines," by Bhagirath, et al.
Table of Contents
Research Papers
Toward radiomics for assessment of response to systemic therapies in lung cancer
| Toward radiomics for assessment of response to systemic therapies in lung cancer |
|
https://doi.org/10.18632/oncotarget.27847 Shawn Sun, Florent L. Besson, Binsheng Zhao, Lawrence H. Schwartz, and Laurent Dercle |
| 4677-4680 |
| Abstract | PDF | Full Text | How to cite |
MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer
| MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer |
|
https://doi.org/10.18632/oncotarget.27849 Divya Bhagirath, Thao Ly Yang, Theresa Akoto, Nikhil Patel, Laura Z. Tabatabai, and Sharanjot Saini |
| 4681-4692 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |
NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy
| NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy |
|
https://doi.org/10.18632/oncotarget.27845 Yvonne Cornejo, Min Li, Thanh H. Dellinger, Rachael Mooney, Masmudur M. Rahman, Grant McFadden, Karen S. Aboody, and Mohamed Hammad |
| 4693-4698 |
| Abstract | PDF | Full Text | How to cite |
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
| miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells |
|
https://doi.org/10.18632/oncotarget.27840 Nicholas J. Monteleone, and Carol S. Lutz |
| 4699-4721 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
| PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer |
|
https://doi.org/10.18632/oncotarget.27846 Michael Rees, Chris Smith, Peter Barrett-Lee, and Steve Hiscox |
| 4722-4734 |
| Abstract | PDF | Full Text | How to cite |
Differential gene expression in cisplatin-resistant and -sensitive testicular germ cell tumor cell lines
| Differential gene expression in cisplatin-resistant and -sensitive testicular germ cell tumor cell lines |
|
https://doi.org/10.18632/oncotarget.27844 Jan Roška, Lenka Wachsmannová, Lenka Hurbanová, Zuzana Šestáková, Thomas Mueller, Dana Jurkovičová, and Miroslav Chovanec |
| 4735-4753 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme
| Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme |
|
https://doi.org/10.18632/oncotarget.27842 Vishnu S. Mishra, Naveen Kumar, Masoom Raza, and Seema Sehrawat |
| 4754-4769 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
Alphastatin-C a new inhibitor of endothelial cell activation is a pro-arteriogenic agent in vivo and retards B16-F10 melanoma growth in a preclinical model
| Alphastatin-C a new inhibitor of endothelial cell activation is a pro-arteriogenic agent in vivo and retards B16-F10 melanoma growth in a preclinical model |
|
https://doi.org/10.18632/oncotarget.27839 Adilson Kleber Ferreira, Brunella Cristofaro, Milene Cristina Menezes, Ana Karina de Oliveira, Alexandre Keiji Tashima, Robson Lopes de Melo, Cristiane Castilho Fernandes Silva, Miryam Guillermina Palomino Rodriguez, Daniela Cajado de Oliveira Souza Carvalho, Ricardo Alexandre de Azevedo, Paulo Luiz de Sá Junior, Lisley Inata Mambelli, Fernanda Vieira Portaro, Luc Pardanaud, Anne Eichmann, Osvaldo Augusto Sant’Anna, and Mxarcella Faria |
| 4770-4787 |
| Abstract | PDF | Full Text | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals